검색어: imunokompromitirani (크로아티아어 - 영어)

imunokompromitirani
immunocompromised

imunokompromitirani bolesnici
immunocompromised patients

teško imunokompromitirani bolesnici.
patients in a severely immunocompromised state

imunokompromitirani ispitanici 21 dan kasnije
immunocompromised subjects 21 days after

imunokompromitirani pojedinci (vidjeti dio 4.3)
immunocompromised individuals (see section 4.3)

u klinička ispitivanja nisu bili uključeni imunokompromitirani bolesnici ni bolesnici s teškom neutropenijom.
patients who were immunocompromised and patients with severe neutropenia were excluded from clinical trials.

imunokompromitirani zdravstveni radnici i trudnice ne smiju pripremati i primjenjivati lijek imlygic;
immunocompromised and pregnant healthcare professionals should not prepare and administer imlygic.

riziku su posebno izloženi imunokompromitirani bolesnici koji prethodno nisu imali vodene kozice ili ospice.
immunocompromised patients who have not previously had chickenpox or measles are particularly at risk.

imunokompromitirani bolesnici i bolesnici u kojih je u tijeku sistemsko imunosupresivno liječenje isključeni su iz kontroliranih kliničkih ispitivanja.
immunocompromised patients and patients taking systemic immunosuppressive therapy were excluded from controlled clinical trials.

bolesnici s oslabljenim imunološkim sustavom (imunokompromitirani bolesnici) liječeni lijekom imlygic koji pate od istodobne infekcije
patients with a weakened immune system (immunocompromised patients) treated with imlygic and suffering from concomitant infection

propisivači se upozoravaju na rizik od lažno negativnog tuberkulinskog kožnog testa, posebno u bolesnika koji su teško bolesni ili imunokompromitirani.
prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.

imunokompromitirani bolesnici, kao što su bolesnici s presađenim organom ili dijagnozom sindroma humane imunodeficijencije, nisu se ispitivali u sklopu kliničkog programa saksagliptina.
immunocompromised patients, such as patients who have undergone organ transplantation or patients diagnosed with human immunodeficiency syndrome have not been studied in the saxagliptin clinical programme.

bolesnici su bili imunokompromitirani, s osnovnim stanjima kao što su hematološka zloćudna bolest, neutropenija nakon kemopterapije, gvhd i stanje nakon hsct.
patients were immunocompromised with underlying conditions including haematological malignancy, neutropenia post-chemotherapy, gvhd, and post hsct.

rotarix se mora primijeniti s oprezom u pojedinaca s imunodeficijentnim bliskim kontaktima, kao što su pojedinci s malignim bolestima ili koji su na neki drugi način imunokompromitirani ili pojedinci koji se liječe imunosupresivnim lijekovima.
rotarix should be administered with caution to individuals with immunodeficient close contacts, such as individuals with malignancies, or who are otherwise immunocompromised or individuals receiving immunosuppressive therapy.

bolesnici s povećanim rizikom od oportunističkih infekcija, uključujući imunokompromitirane bolesnike (što uključuje one koji trenutno primaju imunosupresivnu terapiju ili one koji su imunokompromitirani zbog prethodne terapije).
patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies).

kod primjene tysabrija zabilježene su i neke druge oportunističke infekcije, poglavito u bolesnika s crohnovom bolešću koji su imunokompromitirani ili u kojih je postojala značajna komorbidnost, međutim, trenutno nije moguće isključiti povećan rizik od drugih oportunističkih infekcija tijekom primjene lijeka u bolesnika u kojih ne postoji komorbiditet.
other opportunistic infections have been reported with use of tysabri, primarily in patients with crohn’s disease who were immunocompromised or where significant co-morbidity existed, however increased risk of other opportunistic infections with use of the medicinal product in patients without these co-morbidities cannot currently be excluded.

bolesnici koji su teško imunokompromitirani (npr. bolesnici s ozbiljnom urođenom ili stečenom staničnom i/ili humoralnom imunodeficijencijom) (vidjeti dio 4.4).
patients who are severely immunocompromised (e.g. patients with severe congenital or acquired cellular and/or humoral immune deficiency) (see section 4.4).